fenfluramine has been researched along with Weight Gain in 26 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We tested whether 14 wk of dexfenfluramine (30 mg) or fluoxetine (40 mg) treatment would prevent weight gain after subjects quit smoking." | 9.08 | Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. ( el-Khoury, A; Goldberg, H; McDermott, J; Pingitore, R; Spring, B; Wurtman, J; Wurtman, R, 1995) |
| "Directly measured food intake in 31 overweight female smokers to test whether (a) calorie and carbohydrate intakes increase after smoking cessation and (b) double-blind d-fenfluramine (30 mg), a serotonin-releasing drug, suppresses weight gain, overeating, and dysphoric mood associated with stopping smoking." | 9.07 | Weight gain and withdrawal symptoms after smoking cessation: a preventive intervention using d-fenfluramine. ( Gleason, R; Kessler, K; Spring, B; Wurtman, J; Wurtman, R, 1991) |
| "We describe the use of dexfenfluramine (Redux) in six patients with mood disorders (bipolar disorder = 3; major depression = 3) who developed significant weight gain as a result of their psychotropics." | 7.69 | Dexfenfluramine for weight gain secondary to psychotropics. ( Gupta, S; Masand, PS, 1997) |
| "Dexfenfluramine (dF) was compared to placebo as adjuvant to a very energy-restricted diet (1." | 6.67 | Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial. ( Andersen, T; Astrup, A; Quaade, F, 1992) |
| "d-Fenfluramine is an appetite suppressant drug that acts by releasing serotonin from axon terminals and inhibiting its reuptake." | 5.29 | d-fenfluramine in a rat model of dietary fat-induced obesity. ( Bray, GA; Fisler, JS; Underberger, SJ; York, DA, 1993) |
| "We tested whether 14 wk of dexfenfluramine (30 mg) or fluoxetine (40 mg) treatment would prevent weight gain after subjects quit smoking." | 5.08 | Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. ( el-Khoury, A; Goldberg, H; McDermott, J; Pingitore, R; Spring, B; Wurtman, J; Wurtman, R, 1995) |
| "Directly measured food intake in 31 overweight female smokers to test whether (a) calorie and carbohydrate intakes increase after smoking cessation and (b) double-blind d-fenfluramine (30 mg), a serotonin-releasing drug, suppresses weight gain, overeating, and dysphoric mood associated with stopping smoking." | 5.07 | Weight gain and withdrawal symptoms after smoking cessation: a preventive intervention using d-fenfluramine. ( Gleason, R; Kessler, K; Spring, B; Wurtman, J; Wurtman, R, 1991) |
| "We examined the utility of d-fenfluramine, a serotonin-releasing drug previously shown to diminish carbohydrate craving and weight gain in obese people, in treating patients with seasonal affective disorder (SAD), a variant of depression that occurs each fall and winter and is usually associated with hyperphagia and carbohydrate craving." | 5.06 | Nutrient imbalances in depressive disorders. Possible brain mechanisms. ( O'Rourke, D; Wurtman, JJ; Wurtman, RJ, 1989) |
| "We describe the use of dexfenfluramine (Redux) in six patients with mood disorders (bipolar disorder = 3; major depression = 3) who developed significant weight gain as a result of their psychotropics." | 3.69 | Dexfenfluramine for weight gain secondary to psychotropics. ( Gupta, S; Masand, PS, 1997) |
| "Dexfenfluramine (dF) was compared to placebo as adjuvant to a very energy-restricted diet (1." | 2.67 | Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial. ( Andersen, T; Astrup, A; Quaade, F, 1992) |
| "Weight gain was prevented with MTEP (3 mg/kg), and weight and adiposity loss was seen with MTEP (10 mg/kg) and dexfenfluramine." | 1.33 | Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice. ( Anderson, J; Bradbury, MJ; Campbell, U; Chapman, D; Cosford, ND; Giracello, D; King, C; Strack, AM; Tehrani, L; Varney, MA, 2005) |
| "After an additional 12 days of treatment, weight gain decreased significantly accompanied by no appetite suppression." | 1.29 | Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants. ( Shaw, WN, 1993) |
| "d-Fenfluramine is an appetite suppressant drug that acts by releasing serotonin from axon terminals and inhibiting its reuptake." | 1.29 | d-fenfluramine in a rat model of dietary fat-induced obesity. ( Bray, GA; Fisler, JS; Underberger, SJ; York, DA, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.69) | 18.7374 |
| 1990's | 19 (73.08) | 18.2507 |
| 2000's | 3 (11.54) | 29.6817 |
| 2010's | 2 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferro Cavalcante, TC | 1 |
| Marcelino da Silva, AA | 1 |
| Amaral Almeida, LC | 1 |
| Tavares, GA | 1 |
| de Farias Campina, RC | 1 |
| do Nascimento, E | 1 |
| Lopes de Souza, S | 1 |
| Kaplan, LM | 1 |
| Bradbury, MJ | 1 |
| Campbell, U | 1 |
| Giracello, D | 1 |
| Chapman, D | 1 |
| King, C | 1 |
| Tehrani, L | 1 |
| Cosford, ND | 1 |
| Anderson, J | 1 |
| Varney, MA | 1 |
| Strack, AM | 1 |
| Boulé, NG | 1 |
| Chaput, JP | 1 |
| Doucet, E | 1 |
| Richard, D | 2 |
| Després, JP | 1 |
| Bouchard, C | 1 |
| Tremblay, A | 1 |
| Spring, B | 3 |
| Wurtman, J | 2 |
| Wurtman, R | 2 |
| el-Khoury, A | 1 |
| Goldberg, H | 1 |
| McDermott, J | 1 |
| Pingitore, R | 2 |
| Rebuffé-Scrive, M | 1 |
| DePodesta, C | 1 |
| Thys, F | 1 |
| Schapira, M | 1 |
| Ghilain, JM | 1 |
| Maisin, JM | 1 |
| Henrion, J | 1 |
| Shaw, WN | 1 |
| Fisler, JS | 1 |
| Underberger, SJ | 1 |
| York, DA | 1 |
| Bray, GA | 1 |
| Dagnault, A | 1 |
| Deshaies, Y | 1 |
| Yildiz, O | 1 |
| Bolu, E | 1 |
| Deniz, G | 1 |
| Senöz, S | 1 |
| Simşek, A | 1 |
| Ozata, M | 1 |
| Gündogan, N | 1 |
| Gündogan, MA | 1 |
| Fogelson, DL | 1 |
| Yeomans, MR | 1 |
| Clifton, PG | 1 |
| Masand, PS | 1 |
| Gupta, S | 1 |
| Bowden, CL | 1 |
| Dickson, J | 1 |
| Halladay, AK | 1 |
| Fisher, H | 1 |
| Wagner, GC | 1 |
| Andersen, T | 1 |
| Astrup, A | 1 |
| Quaade, F | 1 |
| Kessler, K | 2 |
| Tu, JB | 1 |
| Hartridge, C | 1 |
| Izawa, J | 1 |
| Weintraub, M | 3 |
| Sundaresan, PR | 3 |
| Schuster, B | 2 |
| Averbuch, M | 2 |
| Stein, EC | 2 |
| Cox, C | 2 |
| Byrne, L | 2 |
| Gleason, R | 1 |
| Thakkar, BK | 1 |
| Dastur, DK | 1 |
| Manghani, DK | 1 |
| McCormack, JG | 1 |
| Dean, HG | 1 |
| Jennings, GJ | 1 |
| Blundell, JE | 1 |
| Wurtman, RJ | 1 |
| O'Rourke, D | 1 |
| Wurtman, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000506] | Phase 2 | 0 participants | Interventional | 1983-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for fenfluramine and Weight Gain
| Article | Year |
|---|---|
Pharmacologic therapies for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; | 2010 |
Strategies to minimize weight gain after smoking cessation: psychological and pharmacological intervention with specific reference to dexfenfluramine.
Topics: Behavior; Fenfluramine; Humans; Serotonin Receptor Agonists; Smoking; Smoking Cessation; Weight Gain | 1992 |
8 trials available for fenfluramine and Weight Gain
| Article | Year |
|---|---|
Glucose homeostasis predicts weight gain: prospective and clinical evidence.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Fenfluramine; Glucose Tolerance Test; | 2008 |
Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation.
Topics: Adult; Analysis of Variance; Appetite Depressants; Body Mass Index; Dietary Carbohydrates; Dietary P | 1995 |
Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Diet, Reducing; Double-Blind Method; Energy Intake; Female; Fen | 1992 |
Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase.
Topics: Adult; Behavior Therapy; Body Weight; Diet, Reducing; Double-Blind Method; Drug Therapy, Combination | 1992 |
Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication.
Topics: Adult; Behavior Therapy; Body Weight; Diet, Reducing; Double-Blind Method; Drug Therapy, Combination | 1992 |
Long-term weight control study. VI. Individual participant response patterns.
Topics: Adult; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenflur | 1992 |
Weight gain and withdrawal symptoms after smoking cessation: a preventive intervention using d-fenfluramine.
Topics: Adult; Affect; Arousal; Double-Blind Method; Female; Fenfluramine; Food Preferences; Humans; Middle | 1991 |
Nutrient imbalances in depressive disorders. Possible brain mechanisms.
Topics: Adult; Appetite; Brain; Clinical Trials as Topic; Depressive Disorder; Dietary Carbohydrates; Double | 1989 |
16 other studies available for fenfluramine and Weight Gain
| Article | Year |
|---|---|
Effects of perinatal protein malnutrition and fenfluramine action on food intake and neuronal activation in the hypothalamus and raphe nuclei of neonate rats.
Topics: Animals; Animals, Newborn; Diet, Protein-Restricted; Disease Models, Animal; Eating; Female; Fenflur | 2016 |
Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice.
Topics: Animals; Appetite; Appetite Depressants; Dietary Fats; Eating; Energy Metabolism; Fenfluramine; Food | 2005 |
Effect of dexfenfluramine on fat mass distribution in a high-fat rat model.
Topics: Adipose Tissue; Animals; Dietary Fats; Disease Models, Animal; Fenfluramine; Male; Rats; Rats, Sprag | 1995 |
[Acute pancreatitis and fenfluramine].
Topics: Acute Disease; Female; Fenfluramine; Humans; Middle Aged; Pancreatitis; Weight Gain | 1994 |
Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants.
Topics: Albuterol; Animals; Appetite Depressants; Cyclohexanes; Dextroamphetamine; Drug Tolerance; Eating; E | 1993 |
d-fenfluramine in a rat model of dietary fat-induced obesity.
Topics: Animals; Dietary Fats; Disease Models, Animal; Eating; Fenfluramine; Guanosine Diphosphate; Hypothal | 1993 |
Effects of the 5-hydroxytryptamine agonist D,L-fenfluramine on energy balance in rats: influence of gender.
Topics: Adipose Tissue; Analysis of Variance; Animals; Body Composition; Castration; Eating; Energy Metaboli | 1993 |
Effects of dexfenfluramine on glucose drinking and glucose-conditioned flavour preferences in rats: taste versus post-ingestive conditioning.
Topics: Animals; Conditioning, Classical; Drinking Behavior; Energy Intake; Feeding Behavior; Fenfluramine; | 1996 |
Fenfluramine and the cytochrome P450 system.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Fenfl | 1997 |
Exposure to sweetened solutions enhances the anorectic effect of naloxone but not d-fenfluramine.
Topics: Analysis of Variance; Animals; Appetite Depressants; Eating; Fenfluramine; Male; Naloxone; Narcotic | 1997 |
Dexfenfluramine for weight gain secondary to psychotropics.
Topics: Adult; Antidepressive Agents; Appetite Depressants; Depressive Disorder; Female; Fenfluramine; Human | 1997 |
Mania from dexfenfluramine.
Topics: Anti-Obesity Agents; Bipolar Disorder; Female; Fenfluramine; Humans; Middle Aged; Weight Gain | 1997 |
Effects of phentermine and fenfluramine on alcohol consumption and alcohol withdrawal seizures in rats.
Topics: Alcohol Drinking; Alcohol Withdrawal Seizures; Animals; Appetite Depressants; Drug Interactions; Dru | 2000 |
Psychopharmacogenetic aspects of Prader-Willi syndrome.
Topics: Adolescent; Aggression; Appetite Depressants; Behavior Therapy; Carbamazepine; Combined Modality The | 1992 |
Neuropathology & pathogenesis of experimental fenfluramine toxicity in young rodents.
Topics: Aging; Animals; Brain; Fenfluramine; Mice; Rats; Weight Gain | 1990 |
Effects of chronic low doses of d-fenfluramine on weight gain and calorie intake, brown adipose tissue thermogenic parameters and brain neurotransmitter content in rats fed chow or palatable diets.
Topics: Adipose Tissue, Brown; Animals; Body Temperature Regulation; Brain Chemistry; Diet; Dopamine; Energy | 1989 |